Shares of Antigenics Inc. (Nasdaq: AGEN) soared $1.25 to $2.78 after the drug research company reported positive results for its treatment of patients with kidney cancer.
Antigenics Reports Positive Trial Results
June 03, 2009 at 13:24 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.